68Gallium- and 90Yttrium-/177Lutetium: “theranostic twins” for diagnosis and treatment of NETs

Rudolf A. Werner, Christina Bluemel, Martin S. Allen-Auerbach, Takahiro Higuchi, Ken Herrmann

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Abundant expression of somatostatin receptors (SSTR) is frequently identified in differentiated neuroendocrine tumors and may serve as potential target for diagnostic imaging and treatment. This article discusses the “theranostic approach” of SSTR-targeting compounds including an overview of its role for diagnosis, staging and restaging, discussing its way to being established in clinical routine, and giving an outlook about further potentially relevant developments.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalAnnals of nuclear medicine
Volume29
Issue number1
DOIs
Publication statusPublished - Jan 1 2015
Externally publishedYes

Keywords

  • Neuroendocrine tumor
  • PET/CT
  • PRRT
  • Radionuclide therapy
  • SPECT/CT
  • Theranostic

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of '<sup>68</sup>Gallium- and <sup>90</sup>Yttrium-/<sup>177</sup>Lutetium: “theranostic twins” for diagnosis and treatment of NETs'. Together they form a unique fingerprint.

  • Cite this